Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Adial Pharmaceuticals (ADIL) Operating Expenses (2022 - 2024)

Adial Pharmaceuticals' Operating Expenses history spans 3 years, with the latest figure at $1.9 million for Q4 2024.

  • For Q4 2024, Operating Expenses rose 116.93% year-over-year to $1.9 million; the TTM value through Dec 2024 reached $6.8 million, up 13.85%, while the annual FY2025 figure was $7.8 million, 5.85% down from the prior year.
  • Operating Expenses for Q4 2024 was $1.9 million at Adial Pharmaceuticals, down from $2.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $3.2 million in Q2 2022 and bottomed at $390139.0 in Q1 2024.
  • The 3-year median for Operating Expenses is $2.1 million (2022), against an average of $2.0 million.
  • The largest YoY upside for Operating Expenses was 116.93% in 2024 against a maximum downside of 82.8% in 2024.
  • A 3-year view of Operating Expenses shows it stood at $2.0 million in 2022, then crashed by 55.31% to $894649.0 in 2023, then skyrocketed by 116.93% to $1.9 million in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Operating Expenses are $1.9 million (Q4 2024), $2.2 million (Q3 2024), and $2.3 million (Q2 2024).